You are here

Practice Management

 

New research looking at the efficacy of rivaroxaban, an oral blood-thinning medication compared to aspirin yielded positive results for the complex drug, showing that it can limit the recurrence of a venous thromboembolism (VTE) without increasing the risk for bleeding.

Patients with hypertension who received an electronic counseling intervention had a 10.1 mmHg reduction in systolic blood pressure after a year compared with a six mmHg reduction for a control group, according to a randomized, double-blind controlled trial in Canada.

An analysis of two randomized trials found that taking bococizumab had no benefits with regards to reducing the risk of major adverse cardiovascular events in lower cardiovascular risk patients.

Inclisiran, a PCSK9 synthesis inhibitor designed to lower cholesterol levels in the blood, was shown to significantly lower low-density lipoprotein cholesterol (LDL-C) while maintaining standards of safety and tolerability for every single patient in a clinical trial, a triumph in treatment for cardiovascular disease caused by high cholesterol. 

Although patients with atherosclerotic cardiovascular disease and high levels of low-density lipoprotein (LDL) cholesterol benefited from receiving evolocumab plus statin therapy, the results of the randomized FOURIER trial did not impress Wall Street as shares of the drug’s manufacturer, Amgen, declined shortly after the findings were announced.

 

Recent Headlines

ACC.17: Rivaroxaban more effective in preventing VTE recurrence than aspirin, EINSTEIN CHOICE study shows

New research looking at the efficacy of rivaroxaban, an oral blood-thinning medication compared to aspirin yielded positive results for the complex drug, showing that it can limit the recurrence of a venous thromboembolism (VTE) without increasing the risk for bleeding.

ACC.17: Electronic counseling intervention may benefit patients with hypertension

Patients with hypertension who received an electronic counseling intervention had a 10.1 mmHg reduction in systolic blood pressure after a year compared with a six mmHg reduction for a control group, according to a randomized, double-blind controlled trial in Canada.

ACC.17: Discontinued PCSK9 inhibitor benefits high-risk patients in trial

An analysis of two randomized trials found that taking bococizumab had no benefits with regards to reducing the risk of major adverse cardiovascular events in lower cardiovascular risk patients.

ACC.17: ORION-1 trial provides encouraging results on cholesterol-lowering inhibitor

Inclisiran, a PCSK9 synthesis inhibitor designed to lower cholesterol levels in the blood, was shown to significantly lower low-density lipoprotein cholesterol (LDL-C) while maintaining standards of safety and tolerability for every single patient in a clinical trial, a triumph in treatment for cardiovascular disease caused by high cholesterol. 

ACC.17: FOURIER trial meets primary endpoint, but investors are not impressed

Although patients with atherosclerotic cardiovascular disease and high levels of low-density lipoprotein (LDL) cholesterol benefited from receiving evolocumab plus statin therapy, the results of the randomized FOURIER trial did not impress Wall Street as shares of the drug’s manufacturer, Amgen, declined shortly after the findings were announced.

OIG: Hospitals often do not appropriately bill for certain heart procedures

In 2011 and 2012, hospitals in the U.S. did not often comply with Medicare requirements on how to appropriately bill for right heart catheterizations performed during the same patient encounter as heart biopsies, according to a report from the HHS Office of Inspector General (OIG).

Penn Cardiovascular names Daniel P. Kelly as new director

The Penn Cardiovascular Institute hired Daniel P. Kelly, MD, as its director to oversee a team of basic, translational and clinical researchers.

AHA does not recommend omega-3 fish oil supplements to prevent heart disease

An analysis of randomized clinical trials found that the general population should not use omega-3 fish oil supplements to prevent heart disease, according to a science advisory from the American Heart Association (AHA).

Suboptimal diet accounts for more than 400,000 cardiovascular deaths per year

In 2015, a suboptimal diet accounted for 222,100 cardiovascular disease deaths among men and 193,400 cardiovascular disease deaths among women in the U.S., according to an analysis of national data.

Fainting guidelines instruct physicians to search for heart conditions

A set of guidelines on how fainting could be a sign of a serious heart condition was recently issued by the American College of Cardiology, American Heart Association and the Heart Rhythm Society.

Pages